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a  b  s  t  r  a  c  t
Objective: To evaluate bone mass accrual and determine the inﬂuence of clinical, anthropo-
metric, dietary and biochemical parameters on bone mass.
Methods: A cohort study including 35 prepubertal HIV-infected children, between 7 and 12
years,  attended at a referral center. At time 1 (T1) and time 2 (T2), patients were assessed
according to clinical, anthropometric, dietary, biochemical parameters and bone mineral
density (BMD). At T2, patients were divided into prepubertal and pubertal.
Results: Despite the increase in bone mass absolute values, there was no improvement in
lumbar spine BMD (LSBMD) Z-score (p = 0.512) and worsening in total body BMD  (TBMD)
Z-score (p = 0.040). Pubertal patients (n = 19) showed higher bone mineral content (BMC)
(p  = 0.001), TBMD (p = 0.006) and LSBMD (p = 0.002) compared to prepubertal patients. After
multivariate linear regression analysis, the predictors of bone mass in T1 were age, BMI  and
HA Z-scores for BMC; BMI Z-score, adequate serum magnesium concentration and dietary
calcium intake for TBMD; adequate serum concentration of magnesium, BMI  and HA Z-
scores for LSBMD. In T2, age, total body fat and lean body mass (kg) for BMC; BMI Z-score
and puberty for TBMD; dietary fat intake, BMI Z-score for BMD and puberty for LSBMD.
Conclusion: HIV-infected children have compromised bone mass and the presence of puberty
seems to provide suitability of these parameters. Adequate intake of calcium and fat appearsoperto  be protective for prstatus and serum magnes
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Introduction
Recent advances in antiretroviral therapy allowed more  chil-
dren and adolescents infected with HIV to enter adulthood.
Furthermore, these patients usually develop early clinical and
metabolic abnormalities, including low bone mineral density
for chronologic age.1–3 As a result, there is increased risk of
bone fractures as well as the development of osteopenia and
osteoporosis.1–3
Recent studies have evaluated bone mass in HIV-infected
patients in different age groups. In American and Puerto Rican
patients, HIV-infected children had a higher prevalence of Z-
scores less than or equal to −2 for total body bone mineral
density (TBMD) when compared to HIV-exposed uninfected
subjects (7% vs. 1%, p = 0.008).3 A Dutch cross-sectional study
reported that 8% of patients (mean age = 6.7 years) had lower
Z-scores of lumbar spine bone mineral density (LSBMD).4 A
Brazilian study showed that 32.4% of 74 pubertal adolescents
(mean age = 17.3 ± 1.8 years) had BMD  ≤ −2 of total body or
lumbar spine.1 Another Brazilian study of 48 patients aged
7–17 years reported low BMD  in 10.4%.2
The accrual of bone mass increases during childhood,
accelerates its growth during adolescence, and peak bone
gain stabilizes at the beginning of the third decade of life.5
A chronic disease such as HIV/AIDS leads to the production
of pro-inﬂammatory cytokines (IL-1, IL-6, IL-17, and TNF-),
which may exacerbate the activity of osteoclasts and also
suppress osteoblast activity or cause apoptosis.6,7 The virus
may also enhance the receptor activator of nuclear factor
kappa-B ligand (RANKL), which stimulates osteoclastogen-
esis and subsequent bone loss. The extra production and
osteoclastic activity result in bone remodeling imbalance and
increased bone resorption.6,7 Another mechanism involved in
bone remodeling is the OPG (osteoprotegerin)/RANK (recep-
tor activator of nuclear factor kappaB)/RANKL system, which
regulates the development and activation of osteoclasts.8,9
Many  demographic, genetic, hormonal, nutritional, and
other factors may all affect bone growth. Additionally, early
exposure to antiretroviral drugs since the intrauterine period
and chronic use of antiretroviral drugs throughout life neg-
atively inﬂuence bone mass in the HIV-infected pediatric
population.1,7 This study followed longitudinally prepubertal
HIV-infected patients for two and a half years in order to eval-
uate bone mass accrual and to determine the inﬂuence of
clinical, anthropometric, dietary, and metabolic factors on this
process.
Methods
Study  design  and  sample
A prospective cohort study including prepubertal HIV-infected
children of both sexes, between 7 and 12 years 11 months, was
conducted at the Care Center of Pediatric Infectious Diseases
(CEADIPe), Department of Pediatrics, Universidade Federal de
São Paulo – UNIFESP. The research project was approved by
the Ethics Committee/UNIFESP (project number CEP 0505/08)
and the Informed Consent Forms were signed by the legal 1 5;1  9(6):623–630
guardians. Out of 52 prepubertal patients receiving regular
care at CEADIPe, 40 met  the eligibility criteria for this study at
time 1 (T1). At time 2 (T2), 24 ± 6 months thereafter, 35 addi-
tional patients joined this study, of whom, two  died and three
moved out of the study area.
Methods
Patient’s data, such as mode of HIV transmission, use of pro-
phylaxis for vertical HIV transmission, clinical and immuno-
logical classiﬁcation of disease,10 and current antiretroviral
therapy were abstracted from the medical records. At T1, after
evaluation by pediatricians, only subjects in Tanner puber-
tal stage 1 were included.11 At T2, pubertal outcome was
reassessed. Measurements were performed in the morning
during routine visits to the clinic. None of the children were
hospitalized or receiving enteral or parenteral nutrition ther-
apy at the time. Body weight was assessed to the nearest 0.1 kg,
with each child wearing only light clothing and no shoes.
Height was measured to the nearest 0.1 cm while each child
stood with his or her head, shoulders, buttocks, and heels
touching a ﬂat surface, such as a wall. Weight and height
were used to calculate body mass index (IMC) and height/age
(HA) Z-scores, according to WHO,  2007.12 Body composition
assessment was performed by dual-energy X-ray absorptiom-
etry (DXA), performed by one trained technician at both time
points (LUNAR DPX-L, pediatric software version 1.5; LUNAR
Radiation Corporation, Madison, WI,  USA).
Total body fat (TBF) and lean body mass (LBM) were
expressed in absolute values (kilograms – kg) and percent-
age of total weight (%). Bone mineral content (BMC) was
reported in grams, while total body bone mineral density
(TBMD, excluding the head) and lumbar spine bone mineral
density (LSBMD, L1–L4) were expressed in g/cm2 and Z-scores.
The term low bone mineral density for chronologic age was
used for Z-scores at LS and/or TB equal to or lower than
2 standard deviations from the reference data (Z-score ≤ −2
SD).5 The coefﬁcients of variation in DXA for total body fat
(TBF), total lean mass (TLM), bone mineral density (BMD) and
bone mineral content (BMC) were 1.62%, 1.14%, 0.67%, and
1.72%, respectively. HIV plasma viral load was determined by
the bDNA methodology (branched DNA – Versant® – bDNA
HIV-1 RNA 3.0 assay, Bayer Health Care LLC, Bayer Corpora-
tion Tarrytown, NY) with detection range from 50 copies/mL
to 500,000 copies/mL. Plasma CD4 and CD8T lymphocytes
were evaluated by ﬂow cytometry (BD FACSCaliburTM System,
Franklin Lakes, USA).
The following biochemical determinations were performed
using blood serum (System Roche/Hitachi Cobas® c501 chem-
istry analyzer, Roche Diagnostics Ltd., Brazil, IN). Total calcium
values were obtained using the photometric method (refer-
ence: 8.5–10.5 mg/dL). Magnesium levels were estimated using
the colorimetric method (reference: 1.8–2.5 mg/dL), and phos-
phorus levels were estimated by photometric test (reference:
2.5–4.5 mg/dL). Alkaline phosphatase was quantiﬁed by colori-
metric assay (reference 7–12 years <300 UL, girls 13–17 <187,
boys 13–17 <390) and parathyroid hormone (PTH) levels were
estimated by electrochemiluminescence immunoassay (ref-
erence: 15–65 pg/mL). Ionic calcium was determined by the
potentiometric method (ion selective electrode) (reference:
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.2–1.37 mmol/L) (Radiometer Medical® Copenhagen, Den-
ark).
Plasma concentration of 25-hydroxyvitamin D [s25(OH)D]
as determined using high performance liquid chromatogra-
hy (HPLC) method (Chromsystems Instruments & Chemicals
mbH, Munich, Germany). The plasma samples were collected
n the same season of the year for T1 and T2. The intra-assay
oefﬁcient of variation was 3% and the interassay coefﬁcient of
ariation was 3.3%. The reference values were deﬁned accord-
ng to recommendations proposed by Holick et al.13
Quantiﬁcation of food consumption was obtained by a 24-
our diet recall (24HRs). Four 24HRs, in non-consecutive days
nd with one weekend day per participant in each time, were
ollected during each study period. The analysis of macro-
nd micronutrients intake was performed using the soft-
are  dietWin® (Porto Alegre: Brubins Inc., 2008). Estimated
nergy Requirement (EER) was used to deﬁne the daily require-
ent of energy.14 Macronutrients were expressed in grams or
ercentage,14 while micronutrients were categorized accord-
ng to the Estimated Average Requirement (EAR).15,16
tatistical  analysis
tatistical analysis was performed using the software Sta-
istical Package for Social Sciences (SPSS) version 17.0.
hapiro–Wilk test was used for testing normality of data.
ategorical variables were evaluated using McNemar test,
hi-square and Fisher’s exact test, and were presented in
erms of absolute frequencies (n) and relative frequencies (%).
uantitative variables were presented as mean and standard
eviation (SD), evaluated by student’s t-test, or median (mini-
um and maximum), evaluated using the Wilcoxon test and
ann–Whitney test. Pearson’s correlation was used to deter-
ine the degree of linear relationship between the variables
f bone mass and the other covariates. Considering the vari-
bles BMC, TBMD Z-score, and LSBMD Z-score, multiple linear
egressions were applied at T1 (only prepubertal patients) and
2 (pubertal and prepubertal patients). First, all variables listed
n Tables 1 and 2 were included in the univariate model. Only
hose with a signiﬁcant result (p ≤ 0.05) were included in the
ultivariate model, adjusted for age, sex, pubertal stage, and
linical and immunological disease classiﬁcation. All tests
dopted a 5% (p ≤ 0.05) level of signiﬁcance.
esults
rom 52 prepubertal children that received regular care at
EADIPe (2008), ﬁve had cerebral palsy or other genetic syn-
romes and were excluded from this study; permission to
articipate was not given for six other children, and one hospi-
alized patient died during the study period, leaving 40 eligible
atients to complete the study at time 1 (T1). At time 2 (T2),
wo patients had died and three had moved out of the study
rea.
The sample considered for this study consisted of 35
atients, of whom 18 (51.4%) were female. At T2, 16 (45.7%)
atients remained prepubertal and nine (56.3%) were girls.
mong the 19 (54.3%) patients who  became pubescent, 10
52.6%) were boys. Regarding the patients with pubertal5;1 9(6):623–630 625
development, 11 (58%) had Tanner 2, four (21%) had Tanner
3, and four (21%) had Tanner 4.
Most children (n = 34, 97.1%) acquired HIV through vertical
transmission, and in 19 (55.8%) cases there was no antiretro-
viral prophylaxis during pregnancy, childbirth or neonatal
period. The only patient infected by blood transfusion was
diagnosed with AIDS before the age of two. He was included
in this study as he shared the same clinical and metabolic
disorders of other HIV-infected children. At the time data was
collected, six (17.1%) patients in T1 and four (11.4%) in T2 were
not on antiretroviral therapy.
Regarding nutritional status at T1, 82.9% (n = 29) were
eutrophic and 17.1% (n = 6) overweight/obese (n = 6). At
T2, 74.3% (n = 26) remained eutrophic, 17.1% (n = 6) over-
weight/obese and 8.6% (n = 3) were classiﬁed as underweight
(p = 0.223). Short stature was present in 11.4% (n = 4) at T1 and
in 22.9% (n = 8) at T2 (p = 0.125).
Table 1 describes clinical, nutritional and biochemical
tests of HIV-infected patients, in addition to their classiﬁ-
cation according to pubertal stage in T2. Table 2 lists the
values of BMC, TBMD, LSBMD, food intake, and biochemical
markers of the patients. Considering the biochemical param-
eters in both study points, there was no statistical difference
regarding prevalence of adequate concentrations, except for
phosphorus (74.3% vs. 48.6%; p = 0.035). For vitamin D, we
found a prevalence of 14.3% vs. 22.9% of deﬁciency, 48.6%
vs. 25.7% of insufﬁciency, and 37.1% of vs. 51.4% of adequacy
(p = 0.228).
When comparing biochemical markers in prepubertal vs.
pubertal subjects in T2, again no statistical difference was
found considering the prevalence of adequate concentrations.
For vitamin D, the prevalence was 31.3% vs. 15.8% for deﬁ-
ciency, 37.5% vs. 15.8%o for insufﬁciency and 31.3% vs. 68.4%
for adequacy (p = 0.089).
The annual increase of patients’ bone mass was deter-
mined by linear regression analysis. For BMC, it was observed
a gain of 231 ± 67 g (p = 0.002) in absolute values and 23.8 ± 5.0%
(p < 0.001) in percentage, for each year of age. For TBMD, annual
gain absolute values were 0.053 ± 0.016 g (p = 0.002) and relative
gain values were 6.4 ± 1.8% (p = 0.001), while for LSBMD these
values were an absolute gain of 0.098 ± 0.026 g (p = 0.001), and
a relative gain of 14.8 ± 3.6% (p < 0.001).
Pearsons´ correlation was applied to determine which
covariates were related to the absolute values of bone
mass, expressed in g or g/cm2. At the study endpoint
(T2), the following covariates were positively correlated to
BMC, TBMD, and LSBMD: age (r = 0.514, p = 0.002; r = 0.388,
p = 0.021; r = 0.484; p = 0.004), duration of use of antiretrovi-
rals (r = 0.519, p = 0.001; r = 0.407, p = 0.015; r = 0.450, p = 0.008),
BMI Z-score (r = 0.639, p = 0.000; r = 0.612, p = 0.000; r = 0.615,
p = 0.000), HA Z-score (r = 0.600, p = 0.000; r = 0.460, p = 0.005;
r = 0.462, p = 0.006), total body fat (r = 0.727, p = 0.000; r = 0.637,
p = 0.000; r = 0.652, p = 0.000), and lean body mass (r = 0.877,
p = 0.000, r = 0.679, p = 0.000, r = 0.549, p = 0.001). Alkaline phos-
phatase was positively correlated to BMC  (r = 0.367, p = 0.030)
and LSBMD (r = 0.501, p = 0.003). Dietary magnesium intake
was positively correlated to BMC (r = 0.358, p = 0.035) and
total serum calcium to TBMD (r = 0.348, p = 0.041). HIV viral
load (copies/mL) correlated negatively to total serum cal-
cium (r = −0.459, p = 0.006), BMI Z-score (r = −0.435, p = 0.009),
626  b r a z j i n f e c t d i s . 2 0 1 5;1  9(6):623–630
Table 1 – Clinical, nutritional and biochemical data of HIV-infected patients (n = 35) at time 1 (T1) and time 2 (T2), in
addition to classiﬁcation according to pubertal stage in T2.











Age (years)a 9.6 (1.1) 11.6 (1.2) 0.001 11.2 (1.3) 12.0 (1.1) 0.058
Virological and immunological parameters
Undetectable viral loadc,e 18 (51.4) 17 (48.6) 1.000 8 (50) 9 (47.4) 0.877
CD4+ (cels/mm3)a 756 (393) 701 (430) 0.222 721 (486) 685 (391) 0.813
CD8+ (cels/mm3)a 1099 (595) 1120 (515) 0.768 1155 (556) 1090 (491) 0.715
Nutritional status
Weight (kg)b,a 26.8 (18.2–53.0) 34.3 (21.1–65.5) 0.001 29.8 (5.2) 40.5 (10.4) 0.001
Height (cm)a 131.7 (8.9) 142.3 (10.3) 0.001 134.8 (6.7) 148.6 (8.5) 0.001
BMI Z-scoreb,a −0.23 (−1.9–4.5) −0.51 (−3–2.2) 0.011 −0.72 (−1.06) −0.10 (1.27) 0.058
HA Z-scorea −0.68 (1.1) −0.81 (1.2) 0.086 −1.58 (1.02) −0.17 (1.11) 0.001
Body composition
Total body fat (kg)b,a 4.3 (1.5–18.4) 5.6 (2.0–21.7) 0.001 5.4 (3.4) 8.7 (5.9) 0.048
Total body fat (%)b,a 16.2 (7–35.8) 18.0 (6.8–37.2) 0.235 17.6 (8.5) 20.0 (9.6) 0.434
Lean body mass (kg)b,a 22.4 (17–34.6) 27.7 (17.9–43.8) 0.001 24.4 (3.9) 31.7 (5.9) 0.001
Lean body mass (%)b,a 83.8 (64.2–93) 82.0 (62.8–93.2) 0.235 82.4 (8.5) 80.0 (9.6) 0.434
HIV clinical classiﬁcationc,d n (%) n (%)
B and C 28 (80) 28 (80) 1.000 14 (87.5) 14 (73.7) 0.415
HIV immunological classiﬁcationc,e
1 9 (25.7) 6 (17.1) 0.083 3 (18.8) 3 (15.8) 0.872
2 14 (40.0) 17 (48.6) 7 (43.8) 10 (52.6)
3 12 (34.3) 12 (34.3) 6 (37.5) 6 (31.6)
Time of ARV use (years)b,a 8.4 (0–10.7) 10.1 (0–13.1) 0.001 8.8 (3.1) 10.7 (1.4) 0.019
Use of ARV classesc
PI 19 (54.3) 22 (62.9) 0.508 11 (68.8) 11 (57.9) 0.508
NRTI 29 (82.9) 31 (88.6) 0.625 15 (93.8) 16 (84.2) 0.608
NNRTI 10 (28.6) 8 (22.9) 0.727 4 (25) 4 (21.1) 1.000
ARV, antiretroviral; BMI, body mass index; HA, height for age; PI, protease inhibitors NRTI, nucleoside reverse transcriptase; NNRTI, inhibitors
of reverse transcriptase nucleoside analogs.
Signiﬁcant values are in bold type.
a Student’s t test.
b Median, Wilcoxon test.
c n (%), McNemar test.
d n (%), Fisher test.
e n (%), chi-square test.
TBMD Z-score (r = −0.479, p = 0.004), LSBMD Z-score (r = −0.422,
p = 0.012), CD4+ (r = −0.554, p = 0.000), and lean body mass in kg
(r = −0.399, p = 0.017).
Univariate and multivariate linear regressions were also
used to determine the predictors of BMC, TBMD Z-score, and
LSBMD Z-score for both periods of the study. The ﬁnal results
of the multivariate regression are shown in Tables 3–5.
Discussion
Analyzing the data from all 35 patients in this longitudinal
study of HIV-infected children, there has been an absolute
increase in bone mass values (g or g/cm2) in the period of two
and a half years. However, when Z-scores of LSBMD and TBMD
were compared between T1 and T2, there was no improve-
ment in LSBMD Z-score, while the TBMD Z-score actually
worsened.After evaluation of prepubertal and pubertal children in
T2, signiﬁcantly higher values of BMC, TBMD and LSBMD
were observed in pubertal patients compared to prepubertal
patients.
As result of the inclusion criteria, the samples were homo-
geneous in the two time periods with respect to age, sex,
pubertal stage, and clinical and immunologic classiﬁcation of
the disease. Patients maintained their clinical and immuno-
logical classiﬁcation throughout the study. The number of
patients with undetectable HIV viral load remained the same
at both times. In this study, HIV viral load correlated nega-
tively with TBMD and LSBMD. DiMeglio et al.3 also reported
that disease severity and viral load were inversely correlated
with bone mass.In relation to anthropometric parameters, BMI  Z-score
decreased in T2 and showed a tendency to be lower in
prepubertal children. Adequate BMI  for age is positively corre-
lated with increased bone mass. Patients with compromised
b r a z j i n f e c t d i s . 2 0 1 5;1 9(6):623–630 627
Table 2 – Bone densitometry, biochemical and food intake of HIV-infected patients (n = 35) at time 1 (T1) and time 2 (T2),
in addition to classiﬁcation according to pubertal stage in T2.












BMC (g)a 1071.6 (278.2) 1369 (374.2) 0.001 1103.9 (178.9) 1592.3 (350.3) 0.001
TBMD (g/cm2)a 0.869 (0.068) 0.917 (0.080) 0.001 0.864 (0.052) 0.961 (0.073) 0.001
TBMD Z-scorea −0.054 (0.821) −0.243 (1.018) 0.040 −0.744 (0.914) 0.179 (0.923) 0.006
TBMD Z-score ≤ −2c,d 0.0 (0.0) 2.0 (5.7) 0.500 2.0 (12.5) 0.0 (0.0) 0.202
LSTBMD (g/cm2)a 0.674 (0.100) 0.768 (0.129) 0.001 0.682 (0.071) 0.843 (0.120) 0.001
LSTBMD Z-scorea −0.663 (0.988) −0.731 (1.242) 0.512 −1.419 (0.892) −0.153 (1.215) 0.002
LSTBMD Z-score ≤ −2c,d 2.0 (5.7) 6.0 (17.1) 0.125 5.0 (31.3) 1.0 (5.3) 0.073
Food intake
Energy (kcal)a 1816 (403) 1919 (418) 0.156 1779 (461) 2037 (349) 0.069
Energy < EERc,e 8.0 (22.9) 10.0 (28.6) 0.754 5.0 (31.3) 5.0 (26.3) 0.748
Carbohydrates (g)a 232.4 (56.5) 249.3 (58.4) 0.197 230.9 (62.2) 264.8 (51.7) 0.088
Proteins (g/kg/day)a 2.78 (0.98) 2.25 (0.82) 0.002 2.42 (0.81) 2.18 (0.83) 0.423
Proteins (g)a 76.2 (21.7) 75.2 (17.1) 0.808 72.5 (21.5) 77.3 (13.7) 0.449
Lipids (%)a 32.0 (4.7) 32.2 (4.7) 0.789 31.7 (5.2) 32.7 (4.3) 0.536
Calcium (mg)a 632.5 (251.3) 667.0 (304.3) 0.452 605 (281) 719 (320) 0.278
Calcium < EARc,d 32.0 (91.4) 31.0 (88.6) 1.000 15.0 (93.8) 16.0 (84.2) 0.608
Phosphorus (mg)a 957.7 (233.2) 990.1 (256.8) 0.476 922 (254) 1047 (251) 0.153
Phosphorus < EARc,d 13.0 (37.1) 23.0 (65.7) 0.041 12.0 (75.0) 11.0 (57.9) 0.476
Magnesium (mg)b 227.6 (112.2–500.6) 225.3 (140.3–529.8) 0.883 224 (79) 291 (111) 0.047
Magnesium < EARc,e 4.0 (11.4) 14.0 (40.0) 0.013 8.0 (50.0) 6.0 (31.6) 0.268
Vitamin D (mcg)b 11.0 (0.2–86.1) 9.2 (0.7–80.4) 0.492 4.9 (1.0–76.2) 22.2 (0.7–80.4) 0.201
Vitamin D < EARc,e 17.0 (48.6) 18.0 (51.4) 1.000 9.0 (56.3) 9.0 (47.4) 0.600
Biochemical assay
Total calcium (mg/dL)b 9.4 (8.2–10.8) 9.4 (8.6–9.9) 0.457 9.2 (0.4) 9.5 (0.3) 0.037
Ionic calcium (mmol/L)a 1.2 (0.9) 1.2 (0.7) 0.753 1.17 (0.05) 1.16 (0.09) 0.808
Alkaline phosphatase (UL)a 233.5 (85.3) 236.5 (100.9) 0.883 203.9 (67.7) 263.9 (116.9) 0.080
Phosphorus (mg/dL)a 4.8 (0.5) 4.6 (0.6) 0.075 4.4 (0.7) 4.7 (0.4) 0.200
Magnesium (mg/dL)b 2.0 (1.7–2.7) 2.0 (1.7–3.4) 0.568 1.9 (0.2) 2.1 (0.3) 0.319
Parathormone (pg/mL)b 25.4 (2.9–86.6) 21.8 (4.8–74.9) 0.422 23.4 (14.1) 30.9 (22.3) 0.248
[s25(OH)D] (ng/mL)a 29.2 (10.7) 30.8 (11.1) 0.523 27.2 (10.9) 33.8 (10.5) 0.078
BMC, bone mineral content; TBMD, total body bone mineral density; LSBMD, lumbar spine bone mineral density.
Signiﬁcant values are in bold type.
a Student’s t test.
b Median, Wilcoxon test.
















vn (%), Fisher test.
e n (%), chi-square test.
utritional status, such as underweight or BMI in border-
ine percentiles, have shown lower BMD  Z scores and BMC
alues.1,7 In pubertal patients, height for age Z-score (HAZ),
ean body mass (kg), and fat mass (kg) were signiﬁcantly
reater compared to prepubertal patients. As children get
lder, they are expected to gain weight and lean body mass.
hese changes, characteristics of the growth process, affect
one structure so that bones adapt to the development of the
keleton.17
A cross-sectional study, including American and Puerto
ican patients infected with HIV with a median age of 12.2
10.2–14.4) years, 25% prepubertal, reported that the mean
SD) TBMD and LSBMD Z-scores were 0.06 (1.3) and 0.06 (1.3),
espectively.3 Comparing the above ﬁndings with the results
f this study, TBMD values were similar at T1, while LSBMD
alues were lower in our patients.When prepubescent and pubescent patients at T2 were
compared, we found lower bone mass values in the group that
had not yet sexually developed. Since HIV/AIDS is a chronic
disease, delayed pubertal development may occur frequently.
During adolescence, sex hormones interfere in anthropomet-
ric measurements and body composition and directly increase
bone mass.18,19 Despite adverse factors related to the disease
itself, pubertal patients in this study were able to incorporate
bone mass.
Arpadi et al.20 also reported lower values of total body BMC
in prepubertal HIV-infected children compared to the con-
trol group, matched for age and sex. A study by Jacobson
et al.,19 found similar values of BMC and BMD  at Tan-
ner 1–2, lower BMC at Tanner 3–4, and lower BMC  and
total body and spinal BMD at Tanner 5 in HIV-uninfected
males compared to the control group, demonstrating that
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Table 3 – Predictive variables of bone mineral content
(BMC) (g) at time 1 (T1) and time 2 (T2).
Multivariate linear regression
Variables p  ˇ (SE) 95% CI
T1
Age 0.000 136.5 (16.5) 102.8–170.2
BMI Z-score 0.000 94.7 (17.1) 59.7–129.7
HA Z-score 0.000 87.5 (12.0) 63.0–112.1
T2
Age 0.039 41.4 (19.2) 2.3–80.6
Total body fat (kg) 0.000 28.0 (4.6) 18.5–37.4
Lean body mass (kg) 0.000 37.6 (4.1) 29.2–46.0
SE, standard error; CI, conﬁdence interval; BMI, body mass index;
HA, height for age; kg, kilograms. T1: adjusted R-square of 0.846; T2:
adjusted R-square of 0.893.
Table 4 – Predictive variables of total body bone mineral
density (TBMD) Z-score at time 1 (T1) and time 2 (T2).
Multivariate linear regression
Variables p  ˇ (SE) 95% CI
T1
BMI Z-score 0.000 0.2519 (0.0623) 0.1249–0.3789
Adequate serum
Mg concentration
0.015  0.7917 (0.3062) 0.1672–1.4161
Dietary calcium
intake (mg)
0.026 0.0009 (0.004) 0.0001–0.0017
T2
BMI Z-score 0.000 0.489 (0.090) 0.306–0.671
Puberty 0.013 0.619 (0.235) 0.141–1.097
SE, standard error; CI, conﬁdence interval; BMI, body mass index;
Table 5 – Predictive variables of lumbar spine bone
mineral density (LSBMD) Z-score at time 1 (T1) and time
2 (T2).
Multivariate linear regression




0.002 0.964 (0.277) 0.398–1.529
HA Z-score 0.002 0.276 (0.080) 0.113–0.439
BMI Z-score 0.000 0.353 (0.056) 0.239–0.467
T2
Fat intake (%) 0.000 0.080 (0.020) 0.040–0.121
BMI Z-score 0.000 0.671 (0.071) 0.525–0.816
Puberty 0.000 0.769 (0.188) 0.387–1.152
SE, standard error; CI, conﬁdence interval; BMI, body mass index;
HA, height for age; Mg, magnesium. T1: adjusted R-square of 0.739;Mg, magnesium; T1: adjusted R-square of 0.525; T2: adjusted R-
square of 0.565.
these differences become more  pronounced with advancing
puberty.
Side effects of antiretroviral drugs, presence of opportunis-
tic infections, gastrointestinal symptoms (diarrhea, nausea,
vomiting, malabsorption), a patient’s peculiar eating habits,
food access, and the caregiver’s ability to offer a balanced meal
are all determinants of food intake for this population. The
literature review shows that inadequate supply of macro- and
micronutrients can cause nutritional impairment.21
This study has attempted to reduce any bias found in the
methods of assessing food intake by observing each individ-
ual for four 24-h recalls during each study period. We  found
signiﬁcant associations between dietary fat intake, calcium,
and increase in bone mass. Meta-analysis that examined the
impact of dietary intake of calcium on bone mass concluded
that increased intake of dietary calcium from dairy products
has a positive effect on total body and lumbar spine BMD  in
children.22 Another study found that adolescents with unde-
tectable viral load had higher intakes of energy, carbohydrates
and calcium.1Considering fat intake as a predictor of LSBMD has to be
done with caution, since it represents the percentage of total
fat coming from total energy intake, which does not evaluate
the quality of fat intake. It is known that a diet rich in saturatedT2: adjusted R-square of 0.815.
and trans fats contribute to the development of dyslipidemia
and an increased risk of cardiovascular disease.23 Moreover,
it should be noted that proper intake of fat promotes normal
infant growth and is important for sexual maturation.24 Fat
also plays an important role in the absorption of fat soluble
vitamins, emphasizing that vitamin D plays major role in bone
homeostasis.13
A high rate of deﬁciency and insufﬁciency of vitamin D,
62.9% in T1 and 48.6% in T2, was found in this study. At T2,
this inadequacy tended to be higher in prepubertal (68.7%)
when compared to pubertal patients (31.6%). It is important
to highlight that vitamin D was measured in the same sea-
son in both T1 and T2. The high prevalence of vitamin D
deﬁciency and insufﬁciency found in our study is consistent
with other HIV-studies reported in different geographic areas.
Further investigation is required to identify the cause of low
levels of vitamin D in our population. A study conducted with
31 American HIV-infected children (4.2–24.3 years), using the
same cut-off points criteria, found deﬁciency and insufﬁciency
in 70% and 23% of patients, respectively.25 Another study,
with 81 American patients infected with HIV (13.8 ± 4.1 years),
showed that 89% had deﬁciency (<11 ng/mL) or insufﬁciency
(<30 ng/mL) of vitamin D.26
T1 was conducted in 2008 and we accepted normal refer-
ence values for vitamin D at the time, so patients received
no supplementation. After pickup at T2, using the new break-
points proposed by Holick et al.,13 all patients with deﬁciency
or insufﬁciency were referred to treatment.
The present study found that low serum magnesium
concentrations were associated with worsening of bone
mass indicators. Interestingly, patients who  had biochem-
ical inadequacy of this mineral had adequate intake of
it. HIV infection provides an increase in the requirement
for several micronutrients, including magnesium, which is
essential for bone health and growth. Studies in healthy
subjects reported that low magnesium concentration is
associated with a reduction in parathyroid hormone (PTH)
and vitamin D,27 the onset of inﬂammation with the pro-
duction of pro-inﬂammatory cytokines,28 and endothelial
dysfunction.29 Additionally, magnesium deﬁciency directly
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educes osteoblast activity while increasing osteoclast activity
esulting in greater bone resorption.30
In vitro study reported that magnesium supplementation
ombats endothelial oxidative stress caused by the use
f ritonavir (PI class).31 In rats, magnesium supplemen-
ation attenuated oxidative cardiovascular toxicity induced by
idovudine (AZT, NRTI class).32 The experimental study also
howed that reduced hyperlipidemia, oxidative stress, and
hanges in cardiac dysfunction were caused by the use of
itonavir.33 The literature lacks clinical studies that prove the
eneﬁts of magnesium supplementation in the HIV-infected
opulation; therefore, it is important to monitor this mineral
n these patients.
As this study was conducted in a single referral center, the
umber of patients included was limited to the population
hat could attend regularly. In relation to antiretroviral ther-
py, we  evaluated the class of antiretroviral drug at the time of
ata collection. However, neither every antiretroviral drug and
ts interaction with bone mass was evaluated, nor the patients’
dherence with their medication.
onclusion
ata from the present study allow us to conclude that HIV-
nfected patients have compromised bone mass, although
ubertal patients show relative better values for these
arameters. Adequate intake of calcium and fat aid bone
ass accumulation in these patients, as well as monitor-
ng their nutrition and serum magnesium concentration.
he predictive value of inadequate increases in bone
ass for morbidity and mortality rates in HIV-infected
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